NVS Novartis AG
Company Analysis
Latest News
🔴 Novartis is trading 3.12% down in after-hours trading after three deaths prompt eight trial pauses
Novartis is trading 3.12% down at $155 in after-hours trading after pausing eight autoimmune and neurological rap-cel trials following three patient deaths. -...
Novartis strikes $3.22 billion Alteogen deal, simplifying drug delivery
Novartis AG signed a strategic partnership and license agreement with South Korean biotech Alteogen Inc. The collaboration utilizes Hybrozyme technology to...
🟢 Novartis is trading 6.98% up today after remibrutinib met primary Phase III MS endpoints
Novartis is trading 6.98% up at $162.68 after remibrutinib met the primary endpoints in two Phase III relapsing multiple sclerosis trials, reducing relapse...
Novartis Scores a Big MS Drug Win, but Three Patient Deaths in a Separate Program Cloud the Celebration — Can the Stock Hold Its Gains?
Shares of Novartis jumped 4.3% to $158.55 on September 1 after the Swiss drugmaker reported that its oral pill for relapsing multiple sclerosis cleared two...
🟢 Novartis is trading 4.3% up in pre-market after positive Phase III remibrutinib results
Novartis is trading 4.27% up now at $158.55 after announcing positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis. -...
Dodge & Cox Slashes Novartis (NVS) Position by 89%
Value investing giant Dodge & Cox drastically reduced its stake in Swiss pharmaceutical company Novartis AG (NVS) by 89% during the second quarter of 2026. The...
🔴 Novartis is trading 4.52% down in after-hours trading
Novartis is trading at $153.08, down 4.52% in after-hours trading, with no clear negative company-specific catalyst identified. • Regular session gained 3.74%...
🟢 Novartis is trading 3.22% up today as healthcare stocks rally broadly
Novartis is trading 3.22% up at $159.52 as healthcare stocks rally broadly, with XLV up 3.23% during regular trading. - Investors are rotating toward...
Novartis AG Q2 2026 Earnings Preview: What Analysts Expect on July 21, 2026
Novartis is scheduled to report Q2 2026 results with a consensus revenue estimate of $14.50 billion and an EPS of $2.20, while the stock currently trades at...
Novartis AG Q1 2026 Earnings Preview: What Analysts Expect on April 28, 2026
Novartis AG enters its Q1 2026 earnings report with a consensus revenue estimate of $13.56 billion (+2.5% YoY) and an EPS expectation of $2.11 (-7.5% YoY),...
Novartis Acquires Pikavation for $2 Billion, Defending Breast Cancer Market Lead
Novartis has agreed to acquire Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics. The deal includes an upfront payment of $2 billion. Potential...